Allergan has also been seeking other buyers such as Shire, according to sources familiar with the matter.
Pyott said during the call that external moves were options, "but it would be totally premature to discuss them."
He also said he was watching the national debate about companies that move their tax bases outside the United States and that he expected changes to U.S. tax rules.
Laval, Quebec-based Valeant has acquired roughly a half-dozen companies in the last two years and has set its sights on becoming one of the world's five biggest drug companies.
Read MorePoll: Which M&A deal is best for shareholders?
Valeant bought contact lens maker Bausch & Lomb Holdings for $8.7 billion last year, shortly after acquiring Medicis Pharmaceuticals for $2.6 billion in 2012. Valeant has grown by cutting spending and buying companies or proven products that will boost earnings. The company also domiciles assets in overseas tax havens.
Valeant Chief Financial Officer Howard Schiller said last week that Allergan spent too much on research and development and that its selling, general and administrative expenses were excessive.